StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Autolus Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 15.7%. For fiscal 2025 it was -27.8%, against -12.5% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-27.8%−15.3
FY2024Dec 31, 2024-12.5%−112.5
FY2023Dec 31, 2023100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ2 2026Jun 30, 202655.2%+72.0
Q1 FY2026CQ1 2026Mar 31, 20266.3%+106.1
Q4 FY2025CQ4 2025Dec 31, 2025-4.3%+39161.2
Q3 FY2025CQ3 2025Sep 30, 2025-35.1%−135.1
Q2 FY2025CQ2 2025Jun 30, 2025-16.8%–
Q1 FY2025CQ1 2025Mar 31, 2025-99.9%–
Q4 FY2024CQ4 2024Dec 31, 2024-39165.5%–
Q1 FY2024CQ1 2024Mar 31, 2024100.0%–

More Autolus Therapeutics figures

See a number that looks wrong?